| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Supresorové CD4+ T buňky s konstitutivní expresí -řetězce receptoru pro IL-2 udržují imunologickou self-toleranci a označují se jako regulační T buňky. Ukázalo se, že v experimentálních nádorových modelech deplece těchto buněk zvyšuje léčebný účinek různých protinádorových vakcín. Řada strategií založených na depleci regulačních T buněk je testována v preklinických i klinických testech. Zatímco v experimentálních podmínkách bylo dosaženo uspokojivých výsledků, u pacientů s nádory byly výsledky spíše sporadické. Pro rutinní využívání deplece T regulačních buněk je tedy třebavyřešit ještě řadu problémů, nicméně tato strategie představuje jednu z nejvýznamnějších perspektiv v nádorové imunoterapii, zejména jako silné adjuvans k nádorovým vakcínám. (cs)
- CD4+ T suppressor cells constitutively expressing interleukin-2 receptor chain (CD25) can maintain immunologic self-tolerance and have been designated regulatory T cells (Tregs). In experimental tumour model systems depletion of Treg cells has been shown to augment the therapeutic effect of different cancer vaccines. A variety of strategies for the induction and enhancement of specific anti-tumour immune responses based on Treg depletion are being tested in pre-clinical and clinical settings. Whereas in most experimental tumour models these strategies provided satisfactory results, in cancer patients their success was rather episodic, and many basic as well as technical problems have still to be solved before the therapeutic protocols for the depletion of specific adaptive Tregs in cancer patients can be proposed. Nevertheless, the depletion of Tregs belongs at present to the highlights of prospective cancer immunotherapy, particularly as a potent adjuvant to cancer vaccines.
- CD4+ T suppressor cells constitutively expressing interleukin-2 receptor chain (CD25) can maintain immunologic self-tolerance and have been designated regulatory T cells (Tregs). In experimental tumour model systems depletion of Treg cells has been shown to augment the therapeutic effect of different cancer vaccines. A variety of strategies for the induction and enhancement of specific anti-tumour immune responses based on Treg depletion are being tested in pre-clinical and clinical settings. Whereas in most experimental tumour models these strategies provided satisfactory results, in cancer patients their success was rather episodic, and many basic as well as technical problems have still to be solved before the therapeutic protocols for the depletion of specific adaptive Tregs in cancer patients can be proposed. Nevertheless, the depletion of Tregs belongs at present to the highlights of prospective cancer immunotherapy, particularly as a potent adjuvant to cancer vaccines. (en)
|
| Title
| - Depletion of Treg cells augments the therapeutic effect of cancer vaccines
- Depletion of Treg cells augments the therapeutic effect of cancer vaccines (en)
- Deplece T regulačních buněk zvyšuje terapeutický účinek nádorových vakcín (cs)
|
| skos:prefLabel
| - Depletion of Treg cells augments the therapeutic effect of cancer vaccines
- Depletion of Treg cells augments the therapeutic effect of cancer vaccines (en)
- Deplece T regulačních buněk zvyšuje terapeutický účinek nádorových vakcín (cs)
|
| skos:notation
| - RIV/68378050:_____/06:00047250!RIV07-AV0-68378050
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/06:00047250
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Treg cells; cancer vaccines (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)